Safety and pharmacokinetics of dicloxacillin in healthy chinese volunteers following single and multiple oral doses

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 5687-5695

  Wu, Guolan ^a   Zheng, Yunliang ^a   Zhou, Huili ^a   Hu, Xingjiang ^a   Liu, Jian ^a   Zhai, You ^a   Zhu, Meixiang ^a   Wu, Lihua ^a   Shentu, Jianzhong ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Dicloxacillin; Healthy volunteers; Pharmacokinetics; Safety; Tolerability

Indexed keywords

DICLOXACILLIN; ANTIINFECTIVE AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG SAFETY; DRUG URINE LEVEL; ELECTROCARDIOGRAM; ELIMINATION HALF-LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; KIDNEY FUNCTION TEST; LEUKOPENIA; LIVER FUNCTION TEST; MALE; MAXIMUM PLASMA CONCENTRATION; NEUTROPENIA; NORMAL HUMAN; OPEN STUDY; TREATMENT DURATION; URINALYSIS; VOLUNTEER; ADOLESCENT; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MODEL; BLOOD; CHINA; DRUG ADMINISTRATION; HALF LIFE TIME; METABOLIC CLEARANCE RATE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; TANDEM MASS SPECTROMETRY; URINARY EXCRETION; URINE; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DICLOXACILLIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HALF-LIFE; HEALTHY VOLUNTEERS; HUMANS; LINEAR MODELS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; RENAL ELIMINATION; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84944769157     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S92117     Document Type: Article

References (24)

1. Gravenkemper CF, Bennett JV, Brodie JL, Kirby WM. Dicloxacillin: in vitro and pharmacologic comparisons with oxacillin and cloxacillin. Arch Intern Med. 1965;116:340–345.
2. Bergan T. Penicillins. Antibiot Chemother (1971). 1978;25:1–122.
3. Reimer LG, Stratton CW, Reller LB. Minimum inhibitory and bacteri­cidal concentrations of 44 antimicrobial agents against three standard control strains in broth with and without human serum. Antimicrob Agents Chemother. 1981;19(6):1050–1055.
4. Dimitrova DJ, Pashov DA, Dimitrov DS. Dicloxacillin pharmacokinet­ics in dogs after intravenous, intramuscular and oral administration. J Vet Pharmacol Ther. 1998;21(5):414–417.
5. Zamotaev IP, Sokolova VI, Konstantinova LA, Pozdniakova VP. [Effectiveness of capsules of the sodium salt of dicloxacillin in bron­chopulmonary diseases]. Antibiotiki. 1976;21(3):266–269. Russian.
6. Smith LG. Chronic staphylococcal infections of bone and soft tissue. Treatment with dicloxacillin. J Med Soc N J. 1970;67(5):219–222.
7. Blaszczyk-Kostanecka M, Dobozy A, Dominguez-Soto L, et al. Com­parison of two regimens of oral clindamycin versus dicloxacillin in the treatment of mild-to-moderate skin and soft-tissue infections. Curr Ther Res – Clin Exp. 1998;59(6):341–353.
8. Stewart C, Shaver TS, Flournoy DJ, et al. Methicillin-resistant staphylococcal urinary tract infection treated with dicloxacillin. J Okla State Med Assoc. 1993;86(2):66–68.
9. Nissen JL, Skov R, Knudsen JD, et al. Effectiveness of penicillin, diclox­acillin and cefuroxime for penicillin-susceptible Staphylococcus aureus bacteraemia: a retrospective, propensity-score-adjusted case-control and cohort analysis. J Antimicrob Chemother. 2013;68(8):1894–1900.
10. Knott T, Lange A, Volkening R. [Dicloxacillin, a penicillinase-fast oral penicillin. Antibacterial efficacy and pharmacokinetics in humans]. Arzneimittelforschung. 1965;15(4):331–340. German.
11. Bennett JV, Gravenkemper CF, Brodie JL, Kirby WM. Dicloxacillin, a new antibiotic: clinical studies and laboratory comparisons with oxacillin and cloxacillin. Antimicrob Agents Chemother (Bethesda). 1964;10:257–262.
12. Nauta EH, Mattie H. Dicloxacillin and cloxacillin: pharmacokinetics in healthy and hemodialysis subjects. Clin Pharmacol Ther. 1976;20(1):98–108.
13. Bass JW, Bruhn FW, Merritt WT, et al. Comparison of oral penicillinase-resistant penicillins: contrasts between agents and assays. South Med J. 1982;75(4):408–410.
14. Sutherland R, Croydon EA, Rolinson GN. Flucloxacillin, a new isox­azolyl penicillin, compared with oxacillin, cloxacillin, and dicloxacillin. Br Med J. 1970;4(5733):455–460.
15. Roder BL, Frimodt-Moller N, Espersen F, Rasmussen SN. Dicloxacillin and flucloxacillin: pharmacokinetics, protein binding and serum bac­tericidal titers in healthy subjects after oral administration. Infection. 1995;23(2):107–112.
16. Lofgren S, Bucht G, Hermansson B, et al. Single-dose pharmacokinetics of dicloxacillin in healthy subjects of young and old age. Scand J Infect Dis. 1986;18(4):365–369.
17. Alderete O, Gonzalez-Esquivel DF, Del Rivero LM, Castro Torres N. Liquid chromatographic assay for dicloxacillin in plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;805(2):353–356.
18. Smith AL, Meeks CA, Koup JR, et al. Dicloxacillin absorption and elimination in children. Dev Pharmacol Ther. 1990;14(1):35–44.
19. World Medical Association. Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and amended by the 59th WMA General Assembly, Seoul, Korea; 2008.
20. European Medicines Agency (EMEA). Guidance on Good Clinical Practice. ICH topic E 6 (R1). In: CPMP. London, UK; 2002.
21. China Food and Drug Administration. Guideline for Good Clini­cal Practice. 2003. Available from: http://www.sda.gov.cn/WS01/CL0053/24473.html. Accessed 24 September, 2015.
22. China Food and Drug Administration. Guideline for pharmacokinetics studies of generic drug products. 2005. Available from: http://www.sfda.gov.cn/WS01/CL1616/83420.html. Accessed 24 September, 2015.
23. U.S. Food and Drug Administration. Bioanalytical Method Validation. FDA Center for Drug Evaluation and Research, Rockville, MD; 2001.
24. Putnam WS, Woo JM, Huang Y, Benet LZ. Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics. J Clin Pharmacol. 2005;45(4):411–421.